For Patrick Flanagan, CEO of Veristat, optimism will drive new financial growth.“The coming year will mark a new era of ...

Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage clinical testing for gout.

The UK-US deal does not resolve every challenge – no single agreement could. But it marks a meaningful step toward restoring ...

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Singaporean Health Sciences Authority (HSA) say the ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

Swiss biotech AC Immune has said that its vaccine-like alpha-synuclein-targeted immunotherapy has shown promise in slowing ...

The deal focuses on a weight-loss pill in development at YaoPharma, a GLP-1 agonist codenamed YP05002, which is currently in ...

RNA interference drug developer SanegeneBio leads our round-up of this week's biotech financings, with a $110 million Series ...

Flow Neuroscience has secured FDA approval for its at-home brain stimulation device, the FL-100 wearable device, as a ...

Today, the EU Council and Parliament reached an agreement in principle on the long-awaited pharma reform package, but ...

The move towards a higher threshold for showing efficacy for new CAR-Ts comes after the FDA loosened the requirements for ...